Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amcad BiomedROCO:4188 +1.11%47 Return-on-Tangible-Equity is -11.94% as of Mar. 2026. GuruFocus rates ROCO:4188 with a GF Score™ of 47/100 and a GF Value™ of NT$9.60 (Fairly Valued). The stock has 5 warning signs investors should review. Among 757 Medical Devices & Instruments companies, Amcad Biomed ranks worse than 68.03% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Amcad Biomed's annualized net income for the quarter that ended in Mar. 2026 was NT$-54.06 Mil. Amcad Biomed's average shareholder tangible equity for the quarter that ended in Mar. 2026 was NT$452.87 Mil. Therefore, Amcad Biomed's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -11.94%.
The historical rank and industry rank for Amcad Biomed's Return-on-Tangible-Equity or its related term are showing as below:
ROCO:4188'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -14.53 Med: -10.73 Max: -6.44
Current: -11.56
During the past 13 years, Amcad Biomed's highest Return-on-Tangible-Equity was -6.44%. The lowest was -14.53%. And the median was -10.73%.
ROCO:4188's Return-on-Tangible-Equity is ranked worse than 68.03% of 757
companies
in the Medical Devices & Instruments industry
Industry Median: 4.09
vs ROCO:4188: -11.56
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Amcad Biomed Return-on-Tangible-Equity Related Terms
Amcad Biomed Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Amcad Biomed's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4188 vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Amcad Biomed's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amcad Biomed Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Amcad Biomed's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Amcad Biomed's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -11.94% mean?
Amcad Biomed (ROCO:4188) has a Return-on-Tangible-Equity of -11.94% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Amcad Biomed and its competitors. According to the industry distribution chart, Amcad Biomed ranks #515 out of 757 companies in the Medical Devices & Instruments industry, placing it in the top 68%.
Is Amcad Biomed's Return-on-Tangible-Equity too high?
Amcad Biomed's current Return-on-Tangible-Equity is -11.94%. Based on the distribution chart, Amcad Biomed ranks #515 out of 757 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Amcad Biomed has a GF Score™ of 47/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Amcad Biomed's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Amcad Biomed ranks #515 out of 757 companies for Return-on-Tangible-Equity. This places Amcad Biomed in the lower half of its industry. The industry median Return-on-Tangible-Equity is 4.09. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.09, based on 757 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Amcad Biomed and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amcad Biomed's current Return-on-Tangible-Equity is -11.94%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amcad Biomed stock overvalued right now?
Based on GuruFocus' analysis, Amcad Biomed (ROCO:4188) is currently considered Fairly Valued. The stock's GF Value™ is NT$9.60, compared to a current price of NT$10.05 — trading 4.7% above its estimated fair value. The current Return-on-Tangible-Equity is -11.94%. Amcad Biomed's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Amcad Biomed (ROCO:4188), the current Return-on-Tangible-Equity is -11.94% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amcad Biomed (ROCO:4188) Overvalued in 2026?
Based on GuruFocus' analysis, Amcad Biomed stock appears to be overvalued.
The current stock price of NT$10.05 is trading 4.7% above its estimated GF Value™ of NT$9.60.
GuruFocus considers Amcad Biomed to be Fairly Valued.
Key valuation signals for ROCO:4188:
Return-on-Tangible-Equity: -11.94%
GF Value™: NT$9.60 vs. price of NT$10.05 (4.7% above fair value)
No single metric tells the full story. See the ROCO:4188 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amcad Biomed Corp develops computer-aided detection and diagnosis(CADe/CADx) software devices. Its product pipeline includes AmCAD-UT Detection, AmCAD-UV, AmCAD and AmCAD-UO. Geographically, the company generates revenue from Taiwan, China, Europe, Asia (excluding Taiwan and China), and other countries, out of which the majority of the revenue is generated from Taiwan. The company has two segments: the Medical Diagnostic Software segment, which is responsible for the development and sales of smart medical imaging diagnostic software devices, and the Precision Medical Equipment segment, which is responsible for research, development, manufacturing, and sales of high-end ultrasonic probes. The company generates the majority of its revenue from the Precision Medical Equipment segment.
47GF Score
Get the complete analysis for ROCO:4188
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4188 has been successfully added to your 
